Global Osteosarcoma Pipeline Insights, H1 2020: Therapeutics, Developments, Products, Drugs, Players

DUBLIN, April 27, 2020 /PRNewswire/ -- The "Osteosarcoma - Pipeline Review, H1 2020" drug pipelines has been added to's offering.

This Pharmaceutical and Healthcare pipeline guide provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 29, 10, 2, 32 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 4 and 3 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


    --  The pipeline guide provides a snapshot of the global therapeutic
        landscape of Osteosarcoma (Oncology).
    --  The pipeline guide reviews pipeline therapeutics for Osteosarcoma
        (Oncology) by companies and universities/research institutes based on
        information derived from company and industry-specific sources.
    --  The pipeline guide covers pipeline products based on several stages of
        development ranging from pre-registration till discovery and undisclosed
    --  The pipeline guide features descriptive drug profiles for the pipeline
        products which comprise, product description, descriptive licensing and
        collaboration details, R&D brief, MoA & other developmental activities.
    --  The pipeline guide reviews key companies involved in Osteosarcoma
        (Oncology) therapeutics and enlists all their major and minor projects.
    --  The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based
        on mechanism of action (MoA), drug target, route of administration (RoA)
        and molecule type.
    --  The pipeline guide encapsulates all the dormant and discontinued
        pipeline projects.
    --  The pipeline guide reviews latest news related to pipeline therapeutics
        for Osteosarcoma (Oncology).

Reasons to Buy

    --  Procure strategically important competitor information, analysis, and
        insights to formulate effective R&D strategies.
    --  Recognize emerging players with potentially strong product portfolio and
        create effective counter-strategies to gain competitive advantage.
    --  Find and recognize significant and varied types of therapeutics under
        development for Osteosarcoma (Oncology).
    --  Classify potential new clients or partners in the target demographic.
    --  Develop tactical initiatives by understanding the focus areas of leading
    --  Plan mergers and acquisitions meritoriously by identifying key players
        and it's most promising pipeline therapeutics.
    --  Formulate corrective measures for pipeline projects by understanding
        Osteosarcoma (Oncology) pipeline depth and focus of Indication
    --  Develop and design in-licensing and out-licensing strategies by
        identifying prospective partners with the most attractive projects to
        enhance and expand business potential and scope.
    --  Adjust the therapeutic portfolio by recognizing discontinued projects
        and understand from the know-how what drove them from pipeline.

Key Topics Covered

    1. Introduction
    2. Osteosarcoma - Overview
    3. Osteosarcoma - Therapeutics Development
    4. Osteosarcoma - Therapeutics Assessment
    5. Osteosarcoma - Companies Involved in Therapeutics Development
    6. Osteosarcoma - Drug Profiles
    7. Osteosarcoma - Dormant Projects
    8. Osteosarcoma - Discontinued Products
    9. Osteosarcoma - Product Development Milestones
    10. Appendix

Companies Mentioned

    --  Aadi Bioscience Inc
    --  Advanced BioDesign
    --  Advaxis Inc
    --  Advenchen Laboratories LLC
    --  Allosteros Therapeutics Inc
    --  Amgen Inc
    --  AntiCancer Inc
    --  APEIRON Biologics AG
    --  Arrowhead Pharmaceuticals Inc
    --  Astex Therapeutics Ltd
    --  AstraZeneca Plc
    --  Atlanthera
    --  Aurora BioPharma Inc
    --  Autolus Therapeutics Plc
    --  Bayer AG
    --  BioEclipse Therapeutics Inc
    --  BioMed Valley Discoveries Inc
    --  Boehringer Ingelheim International GmbH
    --  BrightPath Biotherapeutics Co Ltd
    --  Bristol-Myers Squibb Co
    --  Cellectar Biosciences Inc
    --  Cellestia Biotech AG
    --  Cellmid Ltd
    --  CorMedix Inc
    --  CSPC Pharmaceutical Group Ltd
    --  Curamir Therapeutics Inc
    --  Eisai Co Ltd
    --  Eleison Pharmaceuticals LLC
    --  ENB Therapeutics LLC
    --  Endocyte Inc
    --  Exelixis Inc
    --  GlycoMimetics Inc
    --  Hebei Senlang Biotechnology Inc Ltd
    --  HengRui YuanZheng Bio-Technology Co Ltd
    --  ImmunityBio Inc
    --  Intezyne Inc
    --  Iovance Biotherapeutics Inc
    --  Ipsen SA
    --  Isofol Medical AB
    --  Iterion Therapeutics
    --  Jiangsu Hengrui Medicine Co Ltd
    --  Kitov Pharma Ltd
    --  Komipharm International Co Ltd
    --  MacroGenics Inc
    --  Mana Therapeutics Inc
    --  Mateon Therapeutics Inc
    --  MD Biosciences GmbH
    --  Merck & Co Inc
    --  Merck KGaA
    --  MetCure Therapeutics LLC
    --  Nektar Therapeutics
    --  Nkarta Inc
    --  Novartis AG
    --  Oncolix Inc
    --  Ono Pharmaceutical Co Ltd
    --  PEEL Therapeutics Inc
    --  Pfizer Inc
    --  Pimera Inc
    --  Provectus Biopharmaceuticals Inc
    --  Scancell Holdings Plc
    --  Shionogi & Co Ltd
    --  Siena Biotech SpA
    --  Singh Biotechnology LLC
    --  Sorrento Therapeutics Inc
    --  Taiho Pharmaceutical Co Ltd
    --  Taithera Inc
    --  Teijin Pharma Ltd
    --  Transtarget Inc
    --  United Therapeutics Corp
    --  Vaccinex Inc
    --  VCN Biosciences SL
    --  Veana Therapeutics LLC
    --  Y-mAbs Therapeutics Inc

For more information about this drug pipelines report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets